GLP1_NEW
Dulaglutide with macupatide injection
DULAMACU_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.91 (0.14 to 153) | 0.23 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 9.37 (0.60 to 233) | 0.15 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.00 (0.15 to 5.37) | 0.60 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.96 (0.25 to 14.58) | 0.48 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.42 (0.71 to 8.37) | 0.29 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.63 (0.05 to 4.78) | 0.66 |